A phase I trial is currently underway to assess the safety and tolerability of the Menin inhibitor JNJ‐75276617 (developed by Janssen Pharmaceuticals) as both monotherapy and in combination with chemotherapy (NCT05521087) for AML patients with KMT2A‐r, NUP98‐r, and NPM1 mutations. Here, NUP98 is linked to acute myeloid leukemia.